Islet G-protein coupled receptors: therapeutic potential for diabetes
SJ Persaud - Current opinion in pharmacology, 2017 - Elsevier
Highlights•Type 2 diabetes (T2D) is a major healthcare concern.•G-protein-coupled receptor
(GPCR) ligands are used to treat a range of diseases.•Human islets express nearly three
hundred GPCRs.•Only one islet GPCR is currently the target of a clinically used T2D
therapy.•Pharmaceutical companies are developing T2D therapies that activate islet
GPCRs.The incidence of type 2 diabetes (T2D) is increasing at an alarming rate, which is
imposing substantial healthcare and economic burdens worldwide. T2D can be treated by a …
(GPCR) ligands are used to treat a range of diseases.•Human islets express nearly three
hundred GPCRs.•Only one islet GPCR is currently the target of a clinically used T2D
therapy.•Pharmaceutical companies are developing T2D therapies that activate islet
GPCRs.The incidence of type 2 diabetes (T2D) is increasing at an alarming rate, which is
imposing substantial healthcare and economic burdens worldwide. T2D can be treated by a …